MISTI® has moved from research foundation into active product and commercial pathway development.
The next stage is focused on advancing MedMISTI™ towards manufacturability, regulatory readiness, further validation and strategic commercial pathways. This is the window where aligned partners can do more than observe the opportunity.
They can help shape it.
MISTI® has already established important foundations across science, product development and commercial readiness, including:
MISTI® is early stage, but it is not starting from zero.
MISTI® is currently opening its next development round and strategic partnership window to aligned partners who can support:
As the platform matures, future opportunities may include:
MISTI® is at a stage where strategic partners can still influence the development pathway.
That matters.
Once a medical device moves further into design lock, regulatory planning, manufacturing decisions and commercial model development, the opportunity to shape product direction narrows.
Engaging now gives partners the opportunity to explore:
The value of early engagement is not just access.
It is influence.
MISTI’s progress sits across three key areas:
Scientific Foundation, Product Pathway and Commercial Pathway.
MISTI® is built on more than a decade of research and peer reviewed work in surface acoustic wave aerosolisation. The technology has been developed within a research and commercialisation ecosystem that includes institutions and programmes such as the University of Melbourne, the Melbourne Centre for Nanofabrication, ANFF, ANDHealth, MTPConnect and the Medical Device Partnering Program.
MedMISTI™ is the first real world application of the platform: a wearable, breath actuated smart inhalation system designed for more usable and visible respiratory care.
The system includes a liquid cartridge, a transducer that turns liquid into breathable mist, and a reusable wearable face mask.
MISTI’s strategy includes regulatory pathway planning, distribution partnership development, pharmaceutical co-development opportunities and future global commercial pathways. The strategic material identifies goals such as securing 1 to 2 pharmaceutical co-development partnerships, 2 to 3 distribution partnerships and a pathway towards FDA device planning.
This combination matters because MISTI® is not simply presenting a concept. It is building the evidence, product and partnership pathway required to move towards translation.
MISTI® is building a pulmonary delivery platform with an initial application in respiratory care and a broader pathway into advanced inhaled therapeutics.
The first application is MedMISTI™: a wearable, breath actuated smart inhalation system designed to make respiratory treatment easier to use, easier to track and better aligned to real breathing behaviour.
The broader opportunity is a platform that may support multiple high value pathways across respiratory care, biologics, RNA based therapies, public health deployment and strategic healthcare partnerships.
MISTI’s strategic positioning describes the company as a pulmonary drug delivery platform initially proven in breathing compromised patients and built for expansion into biologics, mRNA and advanced therapeutics.
MISTI® is not asking partners to back another inhaler.
It is inviting partners to help shape a pulmonary delivery platform with multiple future pathways.
The right partnership model depends on the role you can play in helping MISTI® advance.
For aligned investors seeking exposure to medtech, connected respiratory care and advanced therapeutic delivery.
Potential collaboration areas:
For pharmaceutical and biotech teams exploring pulmonary delivery for complex or sensitive formulations.
Potential collaboration areas:
For healthcare providers, respiratory clinics, hospitals and care networks interested in usability, evidence generation and care pathway design.
Potential collaboration areas:
For partners with capability in manufacturability, scale up, supply chain, distribution or market access.
Potential collaboration areas:
For government, public health, defence and strategic health agencies focused on access, system resilience and respiratory care deployment.
Potential collaboration areas:
MISTI® is seeking aligned partners with the capability to accelerate the platform, not passive interest alone.
We are especially interested in partners who can bring:
Tell us who you are, where you see strategic fit and what type of engagement you want to explore.
MISTI® welcomes enquiries from aligned investors, pharmaceutical partners, healthcare organisations, medtech collaborators, public health agencies and strategic commercial partners.
MISTI® is advancing from scientific foundation and early validation towards manufacturability, regulatory readiness and commercial pathways.
If you are an aligned investor, pharmaceutical partner, clinical collaborator, manufacturing partner, distribution partner or public health organisation, this is the time to start the conversation.
Find answers about how MedMISTI™ works and what it can do for you
MISTI® is currently seeking aligned investment and strategic partners to support the next stage of development, including usability testing, manufacturability, quality system planning, regulatory readiness, technical benchmarking, drug partnership development and go to market preparation.
MISTI® is opening its next development round to aligned investors and strategic partners. Detailed funding information should be shared through the Expression of Interest process, investor deck or approved data room rather than relying only on public website copy.
The current funding pathway is intended to support human factors testing, proof of concept manufacturing, design refinement, technical benchmarking, IP expansion, quality management system setup, health economics modelling, drug partnership development and go to market preparation.
MISTI® may be relevant to medtech investors, pharmaceutical and biotech companies, healthcare providers, respiratory clinics, public health organisations, government agencies, manufacturing partners, distribution partners and strategic healthcare organisations.
Yes. MISTI® may support pharmaceutical and biotech partners exploring pulmonary delivery for biologics, RNA based medicines, inhaled vaccines, antibiotics, antivirals and other complex formulations that require controlled and formulation conscious delivery.
Potentially, yes. Strategic partners who engage during this stage may be able to contribute to use case selection, evidence requirements, formulation fit, clinical pathway design, market access planning and commercial model development.
Submit an Expression of Interest through the partnership form, outlining your organisation, role, area of interest and preferred type of engagement. MISTI® can then assess alignment with the current development stage and future partnership pathway.
